T2 Biosystems (NASDAQ:TTOO) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of $(1.70) by 17.06 percent. This is a 59.71 percent increase over losses of $(3.50) per share from the same period last year. The company reported quarterly sales of $5.48 million which beat the analyst consensus estimate of $5.40 million by 1.54 percent. This is a 21.45 percent decrease over sales of $6.98 million the same period last year.
T2 Biosystems Q4 EPS $(1.41) Beats $(1.70) Estimate, Sales $5.48M Beat $5.40M Estimate
T2 Biosystems (NASDAQ:TTOO) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of $(1.70) by 17.06 percent. This is a 59.71 percent increase over losses of $(3.50) per share from the
Related Posts
Exane BNP Paribas Upgrades BP to Outperform
Exane BNP Paribas analyst Lucas Herrmann upgrades BP (NYSE:BP) from Neutral to Outperform.
Craig-Hallum Downgrades AXT to Hold
Craig-Hallum analyst Richard Shannon downgrades AXT (NASDAQ:AXTI) from Buy to Hold.
Provention Bio’s Second Try, Apellis’s Eye Disorder Drug Review, 3 Adcom Verdicts And More: November’s Key PDUFA Catalysts Biotech Investors Must Know
Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.